Changes in CSF acetyl- and butyrylcholinesterase activity after long-term treatment with AChE inhibitors in Alzheimer's disease. (Q53313228)

13 May 2018

title

Changes in CSF acetyl- and butyrylcholinesterase activity after long-term treatment with AChE inhibitors in Alzheimer's disease. (English)

1 reference

13 May 2018

6

H Zetterberg

1 reference

13 May 2018

11

K Blennow

1 reference

13 May 2018

7

L Minthon

1 reference

13 May 2018

Lucilla Parnetti

1

object named as

L Parnetti

1 reference

13 May 2018

author name string

D Chiasserini

2

1 reference

13 May 2018

U Andreasson

3

1 reference

13 May 2018

M Ohlson

4

1 reference

13 May 2018

C Hüls

5

1 reference

13 May 2018

A K Wallin

8

1 reference

13 May 2018

N Andreasen

9

1 reference

13 May 2018

V N Talesa

10

1 reference

13 May 2018

language of work or name

English

0 references

publication date

29 September 2010

1 reference

13 May 2018

Acta Neurologica Scandinavica

published in

1 reference

13 May 2018

volume

124

1 reference

13 May 2018

issue

2

1 reference

13 May 2018

page(s)

122-129

1 reference

13 May 2018

Global prevalence of dementia: a Delphi consensus study

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2010.01435.X

Rat brain acetylcholinesterase activity: developmental profile and maturational sensitivity to carbamate and organophosphorus inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2010.01435.X

Acetylcholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimer's fibrils: possible role of the peripheral site of the enzyme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2010.01435.X

Amyloid-beta-Acetylcholinesterase complexes potentiate neurodegenerative changes induced by the Abeta peptide. Implications for the pathogenesis of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2010.01435.X

Clinical pharmacokinetics of galantamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2010.01435.X

Allosterically potentiating ligands of nicotinic receptors as a treatment strategy for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2010.01435.X

Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2010.01435.X

Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2010.01435.X

Changes in the activity and protein levels of CSF acetylcholinesterases in relation to cognitive function of patients with mild Alzheimer's disease following chronic donepezil treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2010.01435.X

Cerebrospinal fluid levels of biomarkers and activity of acetylcholinesterase (AChE) and butyrylcholinesterase in AD patients before and after treatment with different AChE inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2010.01435.X

Altered levels of acetylcholinesterase in Alzheimer plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2010.01435.X

A new and rapid colorimetric determination of acetylcholinesterase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2010.01435.X

Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2010.01435.X

Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2010.01435.X

Cerebrospinal fluid tau and beta-amyloid(1-42) in dementia disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2010.01435.X

Determination of donepezil, an acetylcholinesterase inhibitor, in human plasma by high-performance liquid chromatography with ultraviolet absorbance detection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2010.01435.X

Differential increase in cerebrospinal fluid-acetylcholinesterase after treatment with acetylcholinesterase inhibitors in patients with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2010.01435.X

Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2010.01435.X

Anticholinesterases induce multigenic transcriptional feedback response suppressing cholinergic neurotransmission.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2010.01435.X

Muscarinic acetylcholine receptors activate the acetylcholinesterase gene promoter.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2010.01435.X

Differential mRNA expression of acetylcholinesterase in the central nervous system of rats with acute and chronic exposure of sarin & physostigmine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2010.01435.X

Inhibition of acetylcholinesterase in CSF versus brain assessed by 11C-PMP PET in AD patients treated with galantamine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2010.01435.X

Glycosylation of acetylcholinesterase and butyrylcholinesterase changes as a function of the duration of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2010.01435.X

Rate of progression of cognitive decline in Alzheimer's disease: effect of butyrylcholinesterase K gene variation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2010.01435.X

Sensitivity of butyrylcholinesterase knockout mice to (--)-huperzine A and donepezil suggests humans with butyrylcholinesterase deficiency may not tolerate these Alzheimer's disease drugs and indicates butyrylcholinesterase function in neurotransmis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2010.01435.X

A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2010.01435.X

Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2010.01435.X

Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2010.01435.X

Longitudinal stability of CSF biomarkers in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2010.01435.X

Acetylcholinesterase promotes beta-amyloid plaques in cerebral cortex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2010.01435.X

10.1111/J.1600-0404.2010.01435.X

21 January 2018

Identifiers

DOI

1 reference

13 May 2018

PubMed ID

20880294

1 reference

13 May 2018